GNRH1 and leiomyoma: Because estrogen has been considered the primary driver to stimulate the progression of leiomyoma and accelerate abnormal uterine bleeding, GnRH agonists/antagonists, progestins, selective progesterone receptor modulators (SPRM), and aromatase inhibitors are available to inhibit estrogen actions and productions for leiomyoma-related symptoms [171,172].